Vimarsana
Biggest News Aggregation in the World

Page 13 - Dosage Forms News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dosage Forms. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dosage Forms Today - Breaking & Trending Today

Ankylosing Spondylitis Market Research Report by Drug, by Type of Molecule, by Mechanism Of Action, by Route Of Administration, by Dosage Forms, by End User - Global Forecast to 2025 - Vimarsana News

Ankylosing Spondylitis Market Research Report by Drug, by Type of Molecule, by Mechanism Of Action, by Route Of Administration, by Dosage Forms, by End User - Global Forecast to 2025

Ankylosing Spondylitis Market Research Report by Drug, by Type of Molecule, by Mechanism Of Action, by Route Of Administration, by Dosage Forms, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19 Ankylosing Spondylitis Market Research Report by Drug (Cimzia, Cosentyx, Enbrel, Humira, and Remicade), by Type of Molecule (Biologics and Small Molecules), by Mechanism Of Action, by Route Of Administration, by Dosage Forms, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19 February 24, 2021 08:34 ET | Source: ReportLinker R...

Dr Reddys launches Lansoprazole DR Orally Disintegrating Tablets in U.S. - Vimarsana News

Dr Reddys launches Lansoprazole DR Orally Disintegrating Tablets in U.S.

Food and Drug Administration (USFDA). The Prevacid brand and generic had U. S. sales of approximately $87 million MAT for the most recent twelve months ending in December 2020 according to IMS Health. Dr. Reddy's Lansoprazole DR Orally Disintegrating Tablets are available in 15 mg and 30 mg tablets in unit-dose packages of 100 (10 x 10). Powered by Capital Market - Live News (This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.) Dear Reader, Business Standard has always strived hard to provide up-to-date information and commentary on devel...

Worldwide Sterile Small Molecule Fill/Finish Services Industry to 2030 - Featuring Pfizer CentreOne, Delpharm & Rompharm Among Others - Vimarsana News

Worldwide Sterile Small Molecule Fill/Finish Services Industry to 2030 - Featuring Pfizer CentreOne, Delpharm & Rompharm Among Others

Share this article Share this article ResearchAndMarkets.com's offering. This report features an extensive study of the current market landscape and the future potential of sterile fill/finish services for small molecule drugs. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Small molecule drugs account for nearly 90% of the contemporary therapeutics pipeline. In fact, in 2019, the FDA's Center for Drug Evaluation and Research approved 48 small molecule drugs, representing 70% of the new molecular entities (NMEs) clearing regulat...

Lupin receives USFDA approval for Tavaborole Topical Solution - Vimarsana News

Lupin receives USFDA approval for Tavaborole Topical Solution

The product will be manufactured at Lupin's facility in Pithampur, India. Tavaborole Topical Solution, 5%, is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes. Tavaborole Topical Solution (RLD: Kerydin) had estimated annual sales of USD 76 million in the U. S. (IQVIA MAT December 2020). Powered by Capital Market - Live News (This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.) Dear Reader, Business Standard has always strived hard to provi...

UK begins major trial for new inhaler-based coronavirus treatment - Vimarsana News

UK begins major trial for new inhaler-based coronavirus treatment

Read more about UK begins major trial for new inhaler-based coronavirus treatment on Business Standard. A new potentially life-saving inhaler-based treatment which is hoped will protect COVID-19 patients from developing severe illness has begun a major trial at UK hospitals.